PRECISION FIRST
Emma Wedgwood looks into why the next big thing in 2027 will not be a treatment, but precision.
The most interesting question for 2027 may not be which injectable, device or technique will be the next big thing, but how we use the increasingly sophisticated tools already available to us.
For me, the next stage of aesthetic medicine is about bringing those developments together with better assessment and clinical judgement.
BEYOND THE VOLUME MINDSET
Filler remains an important part of aesthetic medicine, but treatment is moving beyond simply replacing lost volume. Understanding how different products behave in different tissues allows practitioners to select products and techniques according to the individual.
Collagen-stimulating and regenerative treatments are broadening what we can achieve beyond traditional volumisation. A 2026 review in the Journal of Cosmetic Dermatology found the most consistent evidence for sustained tissue remodelling among particulate collagen biostimulators, including poly-L-lactic acid (PLLA), poly-D,L-lactic acid, calcium hydroxyapatite and polycaprolactone. Newer approaches such as polynucleotides, PDRN and extracellular vesicles show promising biological mechanisms, but the clinical evidence for them remains more limited and variable. That distinction matters.
In my view, the future of injectables will be less about choosing between ‘filler’ and ‘regenerative’ treatments and more about understanding what the tissue needs, what each product can realistically achieve and how it fits into the wider treatment plan.
If the last decade of aesthetic medicine was about expanding what we could do, the next will be about becoming more discerning in how we do it
FROM TREATMENTS TO TREATMENT PLANS
The key is knowing where different treatments sit within that plan and what each is being used to achieve. Injectables, collagen biostimulators, energy-based devices and skincare can all influence different aspects of ageing, but combining them effectively requires a clear understanding of anatomy, tissue quality, treatment depth and the expected response.
Rather than following a set protocol, I think we will see more strategic combinations, with the sequence, timing and choice of modalities adapted to the individual patient.
Combining treatments should not mean doing several things simply because they are available. It should mean knowing what each modality contributes, having a clear reason for putting them together and recognising when another treatment adds complexity without improving the outcome.
PREVENTION WITHOUT OVERCORRECTION
The conversation around prevention needs to move beyond the idea that prevention simply means starting injectables earlier.
There is value in recognising changes before they become pronounced, but not every early change needs correcting. Prevention can mean maintaining skin quality, protecting collagen and understanding how someone’s anatomy is likely to change over time, alongside considered decisions about whether treatment is appropriate at all.
I would rather see prevention built around how each individual is likely to age than an expectation that treatment should begin at a particular age.
PRECISION OVER POWER
A similar shift is happening with energy-based treatments. The conversation is becoming less about how powerful a device is and more about how precisely it can target the tissue.
Skin laxity, collagen depletion and changes in skin quality are not the same biological problem, and more sophisticated devices give us further ways of addressing each one. The priority is being clear about what we want to change within the tissue before choosing the technology.
As devices continue to develop, the more useful question is not which is most powerful, but whether its mechanism, depth and treatment parameters suit the patient and the outcome we are aiming for. That moves energy-based treatment away from being technology-led and towards something far more clinically considered.
THE VALUE OF RESTRAINT
If the last decade of aesthetic medicine was about expanding what we could do, the next will be about becoming more discerning in how we do it. We have a deeper knowledge of tissue, more sophisticated injectables, better energy-based technologies and a growing range of treatments designed to influence skin quality and regeneration.
The opportunity now is to bring those advances together in a way that is genuinely individual, using each approach where it adds value rather than treating every concern with the same solution.
That is what makes 2027 so interesting: not the pursuit of the next big treatment, but a more precise, considered and long-term approach to helping patients look like themselves as they age.
EMMA WEDGWOOD
Emma Wedgwood is an advanced nurse practitioner and independent prescriber with over 20 years of medical expertise. Following an extensive career in NHS intensive care, she transitioned to facial rejuvenation in 2018, bringing clinical precision to skin health. Emma holds an MSc in Cosmetic Medicine and serves on the board of BAMAN.